Stem Cell Therapeutics Corp.: Dr. Alan Moore Will Present the Company's Brain and Neural Regeneration Therapy for the Treatment of Stroke and Multiple Sclerosis at the 2009 Banff Venture Forum

• Press Release
• Source: Stem Cell Therapeutics Corp.
• On 8:30 am EDT, Friday October 2, 2009

CALGARY, ALBERTA--(Marketwire - Oct. 2, 2009) - Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS - News) announced that Dr. Alan Moore, President and CEO, will be presenting today at the Banff Venture Forum 2009, taking place in Banff, Alberta, October 1-2. Dr. Moore will be providing an overview of the Company's clinical and pre-clinical stage programs, including progress in the Phase IIb stroke trial with Drs. Steven C. Cramer of the University of California, Irvine and Michael D. Hill of the Foothills Hospital at the University of Calgary, as co-lead investigators; as well as its soon-to-commence multiple sclerosis ("MS") phase II trial with prolactin, lead by Drs. Luanne Metz and Fiona Costello of the MS Clinic at the Foothills Medical Centre in Calgary, Alberta.

Related Quotes

Symbol	Price	Change
SSS.V	0.18	0.00

{"s" : "sss.v","k" : "c10,l10,p20,t10","o" : "","j" : ""}

About the Banff Venture Forum (www.banffventureforum.com): Banff Venture Forum 2009 is the premier company financing event in Canada. It will showcase early and growth stage companies in three streams: Information Technology, Energy Technology and Life Sciences Technology. Featured companies will be presenting before investors from across North America with the intention of securing the investment required to grow their businesses.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE:SSS - News) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

For further information on Stem Cell Therapeutics Corp., visit www.stemcellthera.com.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Alan Moore, PhD
Stem Cell Therapeutics Corp.
President and CEO
(403) 245-5495 ext.224
amoore@stemcellthera.com

Chloe Douglas-Crampton
Stem Cell Therapeutics Corp.
Investor Relations
(403) 245-5495 ext. 221
crampton@stemcellthera.com
www.stemcellthera.com